Abstract:Objective To analyse the clinical effects of Simvastatin combined with Ezetimibe in the treatment of patients with coronary heart disease and its influence for TC, LDL-C, ApoB. Methods From October 2015 to October 2016, 96 patients with coronary heart disease in the Third Branch of Chongqing People's Hospital were selected and divided into control group (48 cases) and observation group (48 cases). The control group was treated by Simvastatin, while the observation group was treated by Simvastatin combined with Ezetimibe. Three months after treatment, the compliance rate and adverse drug reactions of two groups were compared, and the changes of serum cholesterol (TC), low density lipoprotein cholesterol (LDL-C) and apolipoprotein (ApoB) levels were measured before and after treatment between two groups. Results The levels of TC, LDL-C and ApoB in the observation group were lower than those in the control group (P < 0.05). The rate of blood lipid in the observation group was higher than that in the control group, with statistically significant difference (P < 0.05). The incidence of adverse reactions in the observation group was higher than that in the control group, but the difference was not statistically significant (P > 0.05). Conclusion Simvastatin combined with Ezetimibe for coronary heart disease has a good effect in the regulate lipid, which has a high achievement rate of serum lipid and safety of medication.
李民凤 罗秋林 唐前梅▲. 联合应用辛伐他汀和依折麦布治疗冠心病的调脂效果[J]. 中国医药导报, 2017, 14(23): 48-51.
LI Minfeng LUO Qiulin TANG Qianmei▲. Clinical effect of Simvastatin combined with Ezetimibe in the regulate lipid of patients with coronary heart disease. 中国医药导报, 2017, 14(23): 48-51.